Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inari Medical, Inc. (NARI)
NASDAQ:NARI
Holding NARI?
Track your performance easily
NARI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$36.73 - $67.13
Previous Close$53.35
Volume461.46K
Average Volume (3M)892.39K
Market Cap
$3.12B
Enterprise Value$3.04B
Total Cash (Recent Filing)$111.54M
Total Debt (Recent Filing)$32.72M
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Mar 04, 2025EPS Estimate
-$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding58,544,158
10 Day Avg. Volume1,163,865
30 Day Avg. Volume892,391
Standard Deviation0.13
R-Squared0.11
Alpha-0.00220
Financial Highlights & Ratios
Price to Book (P/B)7.18
Price to Sales (P/S)5.24
Price to Cash Flow (P/CF)277.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.30
Enterprise Value/Gross Profit7.01
Enterprise Value/Ebitda-86.21
Forecast
1Y Price Target
$62.55Price Target Upside21.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
Inari Medical News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe PEERLESS trial met its primary endpoint, indicating positive trial results for FlowTriever with less clinical deterioration and less use of intensive care compared to catheter-directed thrombolysis.
Financial PerformanceInari reported a beat-and-raise in Q3 with $153.4M in revenue, driven by its core venous thromboembolism market and reiterated profit expectations.
Market OpportunityThe conversion from catheter-directed thrombolysis could represent a $150M revenue opportunity for Inari.
Bears Say
Competitive LandscapeThe stock may be susceptible to ongoing volatility in the coming quarters, especially with competitors capturing market share.
Legal And Regulatory ChallengesThere is an ongoing DOJ investigation with no clear resolution timeline, which could cause disruption.
Trial ResultsThe trial did not show any statistically significant improvements in all-cause mortality, intercranial hemorrhage, or major bleeding.
---
Ownership Overview
11.13% Insiders
27.76% Mutual Funds
9.41% Other Institutional Investors
26.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NARI FAQ
What was Inari Medical, Inc.’s price range in the past 12 months?
Inari Medical, Inc. lowest stock price was $36.73 and its highest was $67.13 in the past 12 months.
What is Inari Medical, Inc.’s market cap?
Currently, no data Available
When is Inari Medical, Inc.’s upcoming earnings report date?
Inari Medical, Inc.’s upcoming earnings report date is Mar 04, 2025 which is in 111 days.
How were Inari Medical, Inc.’s earnings last quarter?
Inari Medical, Inc. released its earnings results on Oct 28, 2024. The company reported -$0.084 earnings per share for the quarter, beating the consensus estimate of -$0.116 by $0.032.
Is Inari Medical, Inc. overvalued?
According to Wall Street analysts Inari Medical, Inc.’s price is currently Undervalued.
Does Inari Medical, Inc. pay dividends?
Inari Medical, Inc. does not currently pay dividends.
What is Inari Medical, Inc.’s EPS estimate?
Inari Medical, Inc.’s EPS estimate is -$0.02.
How many shares outstanding does Inari Medical, Inc. have?
Inari Medical, Inc. has 58,544,160 shares outstanding.
What happened to Inari Medical, Inc.’s price movement after its last earnings report?
Inari Medical, Inc. reported an EPS of -$0.084 in its last earnings report, beating expectations of -$0.116. Following the earnings report the stock price went up 15.555%.
Which hedge fund is a major shareholder of Inari Medical, Inc.?
Among the largest hedge funds holding Inari Medical, Inc.’s share is Woodline Partners LP. It holds Inari Medical, Inc.’s shares valued at 4M.
---
Inari Medical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$62.55 (21.93% Upside)
$62.55 (21.93% Upside)
Blogger Sentiment
Bullish
NARI Sentiment 66%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 387.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.15%
12-Months-Change
Fundamentals
Return on Equity
-17.72%
Trailing 12-Months
Asset Growth
27.04%
Trailing 12-Months
Company Description
Inari Medical, Inc.
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTreiver product is used for the treatment of pulmonary embolism. Geographically, the company has its presence across the United States.
---
NARI Company Deck
---
NARI Earnings Call
Q3 2024
0:00 / 0:00
---
NARI Revenue Breakdown
96.48% VTE
3.52% Emerging Therapies
---
NARI Stock 12 Month Forecast
Average Price Target
$62.55
▲(21.93% Upside)
Technical Analysis
Inspire Medical Systems
―
Axonics Modulation Technologies
―
Staar Surgical
―
NovoCure
―
Best Analysts Covering NARI
1 Year
1 Year Success Rate
8/16 ratings generated profit
1 Year Average Return
-3.44%
reiterated a buy rating 16 days ago
Copying Larry Biegelsen's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -3.44% per trade.
---